Edition:
India

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

8.45USD
23 Feb 2018
Change (% chg)

$-0.05 (-0.59%)
Prev Close
$8.50
Open
$8.55
Day's High
$8.65
Day's Low
$8.40
Volume
12,707
Avg. Vol
35,504
52-wk High
$16.15
52-wk Low
$6.15

Latest Key Developments (Source: Significant Developments)

Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - END OF PHASE 2 MEETING SCHEDULED FOR HDV IN FEBRUARY 2018.EIGER BIOPHARMACEUTICALS INC - NO SAFETY SIGNALS ATTRIBUTED TO UBENIMEX WERE IDENTIFIED IN PRELIMINARY ANALYSIS.EIGER BIOPHARMACEUTICALS - FURTHER ANALYSIS OF DATA, INCLUDING BIOMARKERS IS ONGOING, ALTHOUGH CO TO DISCONTINUE DEVELOPMENT OF UBENIMEX IN PAH.EIGER BIOPHARMACEUTICALS INC - WILL CONTINUE TO DEVELOP UBENIMEX FOR LYMPHEDEMA BASED ON ITS DISTINCT MECHANISM OF ACTION IMPACTING LYMPHANGIOGENESIS.EIGER BIOPHARMACEUTICALS INC - EIGER IS DEVELOPING UBENIMEX FOR LYMPHEDEMA IN ULTRA STUDY.  Full Article

‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​ as of Oct 31 - SEC filing.  Full Article

Eiger Biopharmaceuticals reports Q3 loss per share $1.10
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :Eiger Biopharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $1.10.Q3 earnings per share view $-1.28 -- Thomson Reuters I/B/E/S.Eiger Biopharmaceuticals - ‍As of Sept 30, 2017, Eiger had cash, cash equivalents and short-term marketable securities of $32.3 million.Eiger Biopharmaceuticals Inc - ‍Company estimates its cash runway now extends into mid-2019​.  Full Article

EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Eiger Biopharmaceuticals Inc :EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 1.8 MILLION SHARES AT $10.00 PER SHARE, BEFORE UNDERWRITING DISCOUNTS & COMMISSIONS​.  Full Article

Eiger BioPharmaceuticals announces proposed public offering of common stock
Friday, 27 Oct 2017 

Oct 26 (Reuters) - Eiger BioPharmaceuticals Inc :Eiger BioPharmaceuticals announces proposed public offering of common stock.Eiger BioPharmaceuticals - ‍intends to use net proceeds of offering to fund clinical development of its portfolio of four product candidates​.  Full Article

Eiger Biopharmaceuticals prices public offering of common stock
Thursday, 18 Aug 2016 

Eiger Biopharmaceuticals Inc : Eiger Biopharmaceuticals announces pricing of public offering of common stock .Says public offering of 1.25 million common shares priced at $16.00per share.  Full Article

Eiger biopharmaceuticals announces proposed public offering of common stock
Thursday, 18 Aug 2016 

Eiger Biopharmaceuticals Inc : Announces proposed public offering of common stock .Eiger Biopharmaceuticals says intends to use net proceeds of offering to fund clinical development of its portfolio of four product candidates.  Full Article

Eiger Biopharmaceuticals Q2 loss per share $1.87
Thursday, 11 Aug 2016 

Eiger Biopharmaceuticals Inc : Q2 loss per share $1.87 . Eiger Biopharmaceuticals reports second quarter 2016 financial results .Q2 earnings per share view $-1.17 -- Thomson Reuters I/B/E/S.  Full Article

Eiger Biopharmaceuticals CFO Welch buys 2500 shares of common stock at avg price of $19.79/shr - SEC filing
Thursday, 23 Jun 2016 

Eiger Biopharmaceuticals Inc :CFO James Welch reports purchase of 2500 shares of company's common stock at average price of $19.79 per share - SEC filing.  Full Article

Eiger Biopharmaceuticals files for mixed shelf of up to $125 mln
Saturday, 18 Jun 2016 

Eiger Biopharmaceuticals Inc : Eiger Biopharmaceuticals Inc files for mixed shelf of up to $125 million . Eiger Biopharmaceuticals Inc files for secondary stock shelf of up to $3.1 million Source: (http://1.usa.gov/268l20n ) Further company coverage: [EIGR.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Eiger to abandon blood pressure drug after trial failure

Eiger BioPharmaceuticals Inc said on Tuesday it would stop development of its blood pressure drug after it failed in a mid-stage study, sending its shares plunging about 46 percent.